TRANSPIRE: Lung Injury in Pediatric HSCT Patients
This study is looking at lung problems that can happen in children and young adults after a hematopoietic stem cell transplant (HSCT). These problems can include diffuse alveolar hemorrhage (DAH), thrombotic microangiopathy (TMA), interstitial pneumonitis (IPS), and bronchiolitis obliterans. The study aims to understand how often these lung injuries occur. We need to learn more about these complications to improve diagnosis and treatment. You may be able to join if you are 24 years old or younger and are having an allogeneic or autologous HSCT. The main goal is to see how many people develop lung injury within 24 months after their transplant. The study plans to enroll 2000 participants, but its current status is unclear.
- Study design
- This is an observational study, meaning researchers will watch and collect information without giving any specific treatments. It plans to include 2000 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will track the incidence of lung injury for 24 months after the HSCT.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
At a glance
Conditions
Where it's being run
9 sites across 8 statesStudy leadership
- Stella Davies, MBBS, PhD, MRCP · PRINCIPAL_INVESTIGATOR · Children's Hospital Medical Center, Cincinnati
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Incidence of Lung Injury after HSCT24 months after HSCT
Participants will be assessed for lung injury at 24 months after HSCT